Arca
Skip to content
Tools
Tools

NS5A: Nonstructural protein 5A

Protein in Hepatitis C virus that 10 drugs act on.

  • Drugs that act on it: 10
  • Approved: 6
  • In phases 1 to 3: 4
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on NS5A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 10

Approved6

  • Velpatasvir
  • Pibrentasvir
  • Daclatasvir
  • Ombitasvir
  • Elbasvir
  • Ledipasvir

Phase 30

    Phase 24

    • Ravidasvir
    • Ruzasvir
    • Odalasvir
    • Samatasvir

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Nonstructural protein 5A inhibitor.
      VelpatasvirApprovedAtea PharmaceuticalsSmall moleculeInhibitor17
      PibrentasvirApprovedAbbVieSmall moleculeInhibitor4
      DaclatasvirBoxed warningApprovedBristol-Myers SquibbSmall moleculeInhibitor2
      OmbitasvirApprovedAbbVieSmall moleculeInhibitor1
      ElbasvirApprovedMerck & Co. (MSD)Small moleculeInhibitor0
      LedipasvirApproved—Small moleculeInhibitor0
      RavidasvirPhase 2Ascletis Pharmaceuticals Co., Ltd.Small moleculeInhibitor1
      RuzasvirPhase 2Atea PharmaceuticalsSmall moleculeInhibitor1
      OdalasvirPhase 2Johnson & JohnsonSmall moleculeInhibitor0
      SamatasvirPhase 2Merck & Co. (MSD)Small moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 15 in all, from ClinicalTrials.gov.
      AI-Powered Hepatitis C Single-Encounter Test-and-TreatVelpatasvirPhase 4Not yet recruitingPatrick GraceAug 28, 2026
      Treatment of CKD Patients With HCVDaclatasvir, OmbitasvirPhase 2 / Phase 3Not yet recruitingTanta UniversityAug 18, 2026
      Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA TreatmentVelpatasvir—Active, not recruitingXiangya Hospital of Central South UniversityMay 4, 2026
      Combating Related Epidemics in HCVVelpatasvirPhase 4Not yet recruitingDuke UniversityApr 30, 2026
      Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World DataPibrentasvir—RecruitingAbbVieFeb 19, 2026
      SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOFRavidasvir—Active, not recruitingCenter of target therapyJan 5, 2026
      Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard StrategyVelpatasvirPhase 4Not yet recruitingANRS, Emerging Infectious DiseasesAug 1, 2025
      Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIVPibrentasvirPhase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)Jun 27, 2025
      C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVRuzasvir, VelpatasvirPhase 3Active, not recruitingAtea Pharmaceuticals, Inc.Jun 25, 2025
      Implementing Low-Barrier HCV Treatment in a Jail SettingVelpatasvirPhase 4RecruitingLifespanMay 1, 2025
      Feasibility and Acceptability of HCV Treatment in PregnancyPibrentasvir—RecruitingWashington University School of MedicineApr 16, 2024
      Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)VelpatasvirPhase 4RecruitingOswaldo Cruz FoundationMar 12, 2024
      The Efficacy of Vosevi in Treating DAA-experienced PatientsVelpatasvir—RecruitingThe Third Affiliated Hospital of Guangzhou Medical UniversityDec 22, 2023
      Study of DAA Treatment for Children and Adolescents With Active HCV Infection in CambodiaDaclatasvirNot applicableActive, not recruitingANRS, Emerging Infectious DiseasesAug 15, 2023
      Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvirPibrentasvirPhase 4RecruitingKirby InstituteFeb 27, 2019

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3307224, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.